Eli Lilly’s Retatrutide Demonstrates Significant Weight Loss While Leaving Cardiovascular Benefit Unclear

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co‑writes The Readout newsletter, and co‑hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Eli Lilly released additional trial results on Thursday, confirming that its next‑generation obesity drug retatrutide produces robust weight loss. However, the data from a study in patients with heart disease do not provide conclusive evidence that the therapy reduces cardiovascular risk.

In the Phase 3 trial, which enrolled roughly 2,000 participants with severe obesity and underlying heart disease (with or without diabetes), patients receiving the highest dose of retatrutide lost an average of 22.6 % of their body weight after 80 weeks. By contrast, those on placebo lost 3.2 % of weight when the analysis was limited to individuals who remained on treatment.

Nevertheless, the study’s secondary cardiovascular endpoints—major events such as death, heart attack, or stroke—did not show a statistically significant reduction in risk for the retatrutide group compared with placebo. Lilly noted that the trial was not designed or powered to definitively assess cardiovascular outcomes and that the incidence of heart events was lower than expected.

Source link